November 14, 2024 5pm London UK time
A Discussion With:
- Diarmaid McDonald
- Sally Gainsbury - Nuffield Trust
- Peter Maybarduk- Public Citizen
- Yannis Natsis - ESIP
An estimated 22 million people worldwide will have cancer in 2030. Policy goals of reducing cancer mortality often default to a discourse of advancing therapeutic strategies, strongly supported by the pharmaceutical industry. However, the impact of cancer therapeutics on survival remains limited. A cancer diagnosis and its treatment, successful or not, impose a heavy burden on patients and their loved ones. Preventing cancers from arising would reduce mortality and the negative social and psychological impact of this disease. Current estimates suggest that at least 30-50% of cancers are preventable with opportunities to go further by better understanding the underlying mechanisms of cancer genesis and risk. In this shared Cancer Research UK and Consilium Scientific webinar, experts in broad aspects of health policy and economics will discuss the historical funding limitations of cancer prevention research compared to therapeutics. What are the current regulatory and economic barriers to advancing cancer prevention? Do we need novel models of health economics to promote cancer prevention? What are the challenges of behavioural and interventional prevention strategies? How can they be overcome? Join us at this webinar focused on highlighting the growing global importance of cancer prevention and the vast opportunities ahead.
Video

